Keloids - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Keloids - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Keloids - Pipeline Review, H1 2015', provides an overview of the Keloids's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keloids
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Keloids
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Keloids Overview 6
Therapeutics Development 7
Pipeline Products for Keloids - Overview 7
Pipeline Products for Keloids - Comparative Analysis 8
Keloids - Therapeutics under Development by Companies 9
Keloids - Therapeutics under Investigation by Universities/Institutes 10
Keloids - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Keloids - Products under Development by Companies 13
Keloids - Products under Investigation by Universities/Institutes 14
Keloids - Companies Involved in Therapeutics Development 15
Delenex Therapeutics AG 15
RestorGenex Corporation 16
RXi Pharmaceuticals Corporation 17
Vida Therapeutics Inc. 18
Keloids - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
CIGB-128 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CM-101 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DLX-1008 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
koebnerisin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
P-529 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
psoriasin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
RXI-109 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
V-2248 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Keloids - Recent Pipeline Updates 41
Keloids - Dormant Projects 47
Keloids - Discontinued Products 48
Keloids - Product Development Milestones 49
Featured News & Press Releases 49
Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 49
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 49
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 50
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 51
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 51
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Keloids, H1 2015 7
Number of Products under Development for Keloids - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Keloids - Pipeline by Delenex Therapeutics AG, H1 2015 15
Keloids - Pipeline by RestorGenex Corporation, H1 2015 16
Keloids - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 17
Keloids - Pipeline by Vida Therapeutics Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Keloids Therapeutics - Recent Pipeline Updates, H1 2015 41
Keloids - Dormant Projects, H1 2015 47
Keloids - Discontinued Products, H1 2015 48